Navigation Links
EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
Date:10/25/2007

Significant Survival Advantage Shown in Lung Cancer Model

ROCKVILLE, Md., Oct. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of interim Phase 1 pharmacokinetic results for its antimitotic agent, ENMD-1198, together with preclinical antitumor activity results. The data were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held this week in San Francisco, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Pharmacokinetic results demonstrate that once a day orally-administered ENMD-1198 has good pharmacokinetic (PK) parameters in cancer patients participating in a Phase 1 clinical study. In the first four cohorts of the dose-escalation trial in advanced cancer patients, ENMD-1198 demonstrated dose proportional PK exposures across the range of 5-30 mg/m2. ENMD-1198, a new chemical entity (NCE) based on a modified chemical structure of 2- methoxyestradiol (2ME2), was designed to decrease metabolism while retaining 2ME2's multiple mechanisms of action, including inducing apoptosis, disrupting microtubules, and inhibiting HIF-1alpha.

ENMD-1198 was evaluated in a preclinical model of non-small cell lung cancer (NSCLC) and demonstrated a three-fold increase in survival compared to Cisplatin, an approved agent for the treatment of this disease. Approximately 80% of the ENMD-1198 treated models remained on study until tumor dissemination evaluation. In prior preclinical stud
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... YORK , 21. Mai 2015 ... DPRX ), ein Unternehmen für ... auf die Entwicklung und Vermarktung von ... konzentriert, kündigte heute eine wissenschaftliche Posterpräsentation ... Phase-III-Zulassungsstudie des Unternehmens vorstellt, OneStep-1 und ...
(Date:5/21/2015)... May 21, 2015  Heidrick & Struggles (Nasdaq: ... , leadership consulting and culture shaping ... among global practices announcing the addition of Tim ... office. Dietlin has extensive life ... and across R&D, Medical and Commercial functions to increase ...
(Date:5/21/2015)... 2015  Today, eight groups representing a ... – Alliance for Patient Access, American Association ... Biologics Prescribers Collaborative, Clinical Immunology Society, Coalition ... North American Society for Pediatric Gastroenterology, Hepatology ... U.S. Food and Drug Administration (FDA) Commissioner ...
Breaking Medicine Technology:Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7Heidrick Increases Healthcare and Life Sciences Expertise 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 3Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 4
... 17, 2011 For the second consecutive year, the ... retailers nationwide which stock the product, according to Nielsen ... types of thermometers, including national brands and private label ... Exergen TemporalScanner™ market share has risen to 20 percent ...
... CHICAGO, May 17, 2011 UBM Canon,s Pharmalot hosted a ... on April 26, 2011. The discussion centered on the ... key questions: How big a vote should procurement get in ... and what should their role be? What should an agency ...
Cached Medicine Technology:UBM Canon's Pharmalot Brings Together a Virtual Panel of Experts to Discuss the Procurement Experience 2UBM Canon's Pharmalot Brings Together a Virtual Panel of Experts to Discuss the Procurement Experience 3
(Date:5/25/2015)... Decora Preset 60 Minute Countdown Timer , ... ‘The Hardware City.’ The product helps in automatically switching off ... and the related electronic device is automatically turned off after ... company said, “We are glad that this amazing product is ... Countdown Timer Switch in just a few clicks. The product ...
(Date:5/24/2015)... 2015 For people who are keen ... Industry, 2009-2019 Market Research Report would be an useful ... study on the present market scenario of this industry. ... growing Chinese market of this industry. The report summarizes ... of the manufacturers in this industry. The report is ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 The ... ( http://www.testosteronelawsuithub.com/ ) has scheduled its next monthly ... the multidistrict litigation. According to court documents filed ... Illinois, the Conference will be convened on June ... Replacement Therapy Product Liability Litigation - MDL No. ...
(Date:5/24/2015)... May 24, 2015 ... CEO - The students were ... at the fourth annual A Day ... at Geneva National in Lake Geneva. ...     -Badger High School,         Jonathan Alfonso,         Bridget ...
(Date:5/23/2015)... 23, 2015 Dr. David Benvenuti, an experienced ... posted a new article to his website that ... Dr Benvenuti explained in the fascinating blog, he has ... their earlobes. , Known as “gauging,” the technique involves placing ... Dr. Benvenuti said will eventually stretch the holes out to ...
Breaking Medicine News(10 mins):Health News:Leviton's Decora 60 Minute Countdown Timer Available On ‘The Hardware City’ 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2
... Researchers have come out with a study that entreats policy makers ... up health plans to combat binge drinking. // , ... , Binge drinking can be described as consuming 10 or more ... women. , According to the researchers, highly educated British women ...
... a collection of nearly 50,000 books, including old and rare ... up here. // ,To be built at the National ... will be one of the biggest ayurveda libraries in India. ... papers and provide exhaustive ayurveda-related information under one roof. ...
... surgical technique pioneered at the University of Alberta has ... tongue cancer.// ,By modifying an existing technique ... tongue, surgeons can provide enough bulk to help improve ... a 'jellyroll'of fat and connective tissue along with the ...
... worldwide research have come up with a microbicidal algal gel ... to evolve into a powerful new protection weapon for women ... efficient. ,Brazilian scientists, who aim to evolve ... assure the gel will be on the market in seven ...
... at Sutton and Merton, the inmates were abused physically and ... long investigation by the Health Care commission. // ,The ... the inmates. These care centres have people who have different ... right kind of mental health. They were under nourished and ...
... article in the January issue of Archives of ... journals, measuring a patient's ratio of white blood ... the similar conditions infectious mononucleosis and bacterial tonsillitis, ... (inflammation of the tonsils) and infectious mononucleosis (caused ...
Cached Medicine News:Health News:Binge Drinking Excessive Among Less Educated Middle-aged Women 2Health News:'Beavertail' Surgery Helps Tongue Cancer Patients 2Health News:'Beavertail' Surgery Helps Tongue Cancer Patients 3Health News:Lymphocyte/WBC Ratio Helps in Treating ENT Disorders 2
Engineered for high volume surgical efficiencies, the Bausch & Lomb Hansatome Microkeratome, a corneal resection instrument, features an automated pivoting motion that provides smooth, resistance-fre...
... The Brilliance 64-channel configuration breaks through ... large volume, thin-slice coverage to improve ... , ,With 40mm of thin-slice coverage, ... imaging, allowing for unprecedented coronary artery ...
Assay for Anti-HTLV-I and Anti-HTLV-II...
InBios' Trypanosoma cruzi (chagas disease) is an ELISA system for the detection of antibodies to T.cruzi derived TcF antigen in human serum or plasma This test is intended for professional in vitro d...
Medicine Products: